

REMARKS

In view of the above, it is submitted that this application is now ready for allowance. Early notice to this effect is solicited. If, in the opinion of the Examiner, a telephone conference would expedite the prosecution of the subject application, the Examiner is invited to call the undersigned at (650) 843-5023.

Respectfully submitted,
COOLEY GODWARD LLP

By: Shelley P. Eberle
Shelley P. Eberle
Reg. No. 31,411

Cooley Godward LLP
Five Palo Alto Square
3000 El Camino Real
Palo Alto, CA 94306-2155
Attention: Patent Group
(650) 843-5000

Attachment: Marked Up Version Of The Specification and Claims Under 37
CFR1.121(b) and (c)

TECHNO-TECHNO

MARKED UP VERSION OF THE SPECIFICATION AND CLAIMS

UNDER 37 CFR1.121(b) and (c)

Pages 10-11, Paragraph [00041]:

[00041] The bioelastomers of the invention can consist of only nonamers (a polynona peptide), tetramers (a polytetrapeptide), only pentamers (a polypentapeptide) or a mixture of these units, but more typically a mixture of tetrapeptide and pentapeptide units (a copolymer). In addition, the bioelastomer can be a copolymer formed from one of the aforementioned monomeric units and a second peptide unit containing 1-100 amino acids, more typically 1-20 amino acids. On the smaller side, this second peptide can be for example, the fibronectin cell attachment sequence, GRGDSP (SEQ ID NO:46) or a monomer such as GVG VAP (SEQ ID NO:47) or VGVAPG (SEQ ID NO:52), which is a chemoattractant for fibroblasts and monocytes. On the larger side (90-100 amino acids), the second peptide can be a cell attachment sequence from the Type-III domains of fibronectin, vitronectin, tenascin, titin [titan] or other related cell attachment protein, which sequence provides more specific cell attachment than the somewhat non-specific GRGDSP cell attachment sequence.

Claim 13 (Amended).

The method of Claim 4 wherein said second peptide unit comprises a cell attachment sequence from the Type-III domains of fibronectin, vitronectin, tenascin, titin [titan] and other related cell attachment proteins.

Claim 34 (Amended).

The method of Claim 23 wherein said tissue site is periurethral, subdermal, tendon or cartilage [cartridge].